Medication info
Combirocan Tablet 5/16 mg

Combirocan Tablet 5/16 mg

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›5.2mg / 1 tabletCandesartan Cilexetil›16mg / 1 tablet
Manufacturer / importer
Hanin Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
30 tablets (10 tablets/PTP x 3)
Approval status
Active

MFDS item code 201803502 · Approved 2018.08.28 · Insurance code 657203350

Summary

Main use
Treatment of hypertension and heart failure; improvement of dyslipidemia; suppression of atherosclerosis progression and cardiovascular risk
Who takes it
Adults · Children
Adult dose
This medicine is for use in adults only. The dose should be individualized for each patient based on the effects and tolerability of each component, candesartan cilexetil and rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatments should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: Administer an initial dose of 4 mg with particular caution in patients at increased risk of hypotension, such as those with volume depletion. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including those undergoing hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience in patients with severe hepatic impairment. 2. Heart failure 1) Adults: An initial dose of 4 mg once daily is recommended. Double the dose at intervals of at least 2 weeks and, based on the patient's tolerability, increase it to a maximum of 32 mg once daily. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue the diet throughout treatment. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score exceeding 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.
Child dose
Essential hypertension: Safety and efficacy have not been established in adolescents and children 18 years of age or younger. Heart failure: Safety and efficacy have not been established in adolescents and children 18 years of age or younger.

Ingredients

Manufacturer
Hanin Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension and heart failure; improvement of dyslipidemia; suppression of atherosclerosis progression and cardiovascular risk

  • Essential hypertension
  • impaired left ventricular systolic function
  • hyperlipidemia
  • familial hypercholesterolemia
  • abnormal beta-lipoproteinemia
  • risk factors for coronary heart disease
  • risk of stroke
  • risk of myocardial infarction
  • risk of arterial revascularization
View approved original text

This medication is used for patients who need to be treated with the two components, Candesartan Cilexetil and Rosuvastatin. Candesartan Cilexetil is effective for patients with essential hypertension and those with heart failure with impaired left ventricular systolic function, especially when an additional ACE inhibitor is needed or if there is poor tolerance. Rosuvastatin is mainly used to treat hyperlipidemia that is not controlled by diet and exercise or familial dyslipidemia. Additionally, it is used as an adjunct to dietary therapy to delay the progression of atherosclerosis and helps reduce the risk of stroke, myocardial infarction, and arterial revascularization in high-risk cardiovascular disease patients. This medication is used for the improvement of health in patients who require control of hypertension and blood cholesterol.

How to take

Adult dose

This medicine is for use in adults only. The dose should be individualized for each patient based on the effects and tolerability of each component, candesartan cilexetil and rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatments should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: Administer an initial dose of 4 mg with particular caution in patients at increased risk of hypotension, such as those with volume depletion. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including those undergoing hemodialysis, is 4 mg; adjust the dose according to the patient's response. Experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min) is limited. 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience in patients with severe hepatic impairment. 2. Heart failure 1) Adults: An initial dose of 4 mg once daily is recommended. Double the dose at intervals of at least 2 weeks and, based on the patient's tolerability, increase it to a maximum of 32 mg once daily. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue the diet throughout treatment. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score exceeding 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.

Child dose

Essential hypertension: Safety and efficacy have not been established in adolescents and children 18 years of age or younger. Heart failure: Safety and efficacy have not been established in adolescents and children 18 years of age or younger.

Precautions

This medication can cause serious harm to the fetus, especially during the second and third trimesters of pregnancy, so it should be discontinued immediately if pregnancy is confirmed. People with an allergy to this medication or its components, those with liver disease or pregnant women, patients with severe liver impairment, and those with myopathy should not use this medication. Elderly patients, those with hyperkalemia, patients with mild to moderate liver disease, etc., should use it with caution and should have liver function and muscle health status checked periodically. This medication may cause serious muscle-related side effects such as muscle pain, myopathy, and rarely rhabdomyolysis, so if there is any pain or weakness in the muscles, consult a doctor immediately. Liver enzyme levels should be checked before and during treatment as abnormal liver function may occur, and if abnormalities are found, the medication should be discontinued. This medication can also affect renal function, so patients with kidney disease or kidney transplant patients should use it cautiously according to their doctor's advice. When taken with other antihypertensive drugs or diuretics, potassium supplements may increase blood potassium levels, so regular blood tests are necessary. This medication may interact with other drugs, so if you are taking any other medications, be sure to inform your doctor or pharmacist. Caution is needed when driving or operating machinery as dizziness or fatigue may occur.

Side effects

Headache, nasopharyngitis, localized infection, fatigue, generalized pruritus, dermatitis, itching, joint stiffness, limb pain, photophobia, dyspepsia, increased blood sugar, decreased blood sodium, hand fractures, hypoglycemia, nephrolithiasis, cough, headache, orthostatic dizziness, itching, nausea, angioedema, hematologic and lymphatic system abnormalities (leukopenia, neutropenia, agranulocytosis), hyperkalemia, hyponatremia, hypoglycemia, dizziness, intestinal vascular edema, diarrhea, increased liver enzyme levels, hepatitis, jaundice, rash, urticaria, angioedema, myalgia, asthenia, increased creatine kinase, rhabdomyolysis, arthralgia, myalgia, low back pain, kidney function impairment, acute kidney failure, interstitial pneumonia, shock, syncope, loss of consciousness, paralysis, hypertonia, syncope, facial flushing, weight gain, facial swelling, thirst, sleep disorders, decreased libido, forgetfulness, poor appetite, increased appetite, tinnitus, dysgeusia, erectile dysfunction, constipation, abdominal pain, pancreatitis, rash, urticaria, myopathy, rhabdomyolysis, asthenia, interstitial lung disease, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe muscle weakness, ocular muscle weakness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture, and it is safe to store at a temperature between 1 degree and 30 degrees Celsius (room temperature). Storing it this way will help maintain the efficacy of the medication for a long time.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

30 tablets (10 tablets/PTP x 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.